Alliance Wealth Advisors LLC Grows Stake in GSK plc (NYSE:GSK)

Alliance Wealth Advisors LLC raised its holdings in shares of GSK plc (NYSE:GSK) by 23.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,918 shares of the pharmaceutical company’s stock after acquiring an additional 1,688 shares during the period. Alliance Wealth Advisors LLC’s holdings in GSK were worth $302,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of GSK. Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its position in GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after purchasing an additional 323 shares in the last quarter. Rehmann Capital Advisory Group lifted its stake in GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares during the last quarter. Investment Partners Asset Management Inc. boosted its holdings in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after purchasing an additional 344 shares in the last quarter. Finally, Bond & Devick Financial Network Inc. raised its holdings in shares of GSK by 5.4% during the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock valued at $320,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $36.03 on Friday. The business has a fifty day simple moving average of $34.25 and a two-hundred day simple moving average of $37.57. The firm has a market capitalization of $74.68 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts forecast that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.36%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 93.08%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday. Six analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.